Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New shot for advanced breast cancer enters first human tests

NCT ID NCT06746688

First seen May 06, 2026 · Last updated May 17, 2026 · Updated 5 times

Summary

This early-stage trial tests a new treatment called ES2B-C001, given alone or with an adjuvant, for people with HER2-positive breast cancer that has spread and hasn't responded to at least two prior therapies. The main goal is to check safety and find the best dose. About 40 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medical University Of Vienna

    RECRUITING

    Vienna, 1090, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Medical University of Graz

    RECRUITING

    Graz, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ordensklinikum Linz GmbH Barmherzige Schwestern

    RECRUITING

    Linz, 4010, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.